GlobalData: HSBC's acquisition of Silicon Valley Bank UK could boost biopharmaceutical companies; deal may increase capital access and global networks for startups, open doors to greater collaborations in driving innovation for drug development

Sample article from our Health Care Sector

March 31, 2023 (press release) –

HSBC’s acquisition of Silicon Valley Bank UK following the collapse of its parent company Silicon Valley Bank may result in new opportunities for biopharmaceutical companies, says  GlobalData, a leading data and analytics company.

According to GlobalData’s Pharma Intelligence Center Deals Database, SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development. In 2018 alone, the company invested over $400 million in venture financing.

Sharon Cartic, Associate Director of Business at GlobalData, comments: “The access to increased capital and international presence that HSBC provides could allow for the potential for biopharmaceutical companies to improve investment in the development of therapies.

“2020 was a record year for venture financing; however, 2021 and 2022 saw less investment as recovery from the COVID-19 pandemic, the Ukraine crisis, and inflation caused market volatility, which resulted in a less favorable environment for risk-averse investors across the biotech industry.”

The Netherlands-based biopharmaceutical company Pharming Group, which develops innovative protein replacement therapies and precision medicines for multiple rare diseases, stated the HSBC acquisition of Silicon Valley Bank UK would allow access to its $19 million deposit and not bear losses. Other European biopharmaceutical companies stated they also expect to recover their deposits. Danish Zealand Pharma, which is involved in the discovery and development of innovative peptide-based medicines, expects to recover its $23.4 million in deposits.

Cartic concludes: “Silicon Valley Bank was a leading provider of venture debt, a type of financing in the form of a loan used by early-stage startup companies to raise capital. It remains to be seen how the void left by the collapse of the bank will be filled and whether there could be a slowdown in venture debt.

“However, the acquisition of Silicon Valley Bank UK by HSBC could provide greater access for biopharmaceutical startups to international markets and global networks of investors. This could open doors to greater biopharmaceutical and startup company collaborations in driving innovation for drug development.”

* Venture financing deals involving SVB Financial Group, SVB Securities, SVB Capital, and Silicon Valley Bank including subsidiaries. Includes all announced and completed venture financing deals globally related to biopharmaceutical drug development

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.